Bristol Myers Squibb gets EMA validation of application for Opdivo plus Yervoy for Hepatocellular Carcinoma Ruchika Sharma21 July 2024 3:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its Type II variation application for...
Zydus Lifscience Gets CDSCO Panel Nod to Manufacture, Market Nivolumab for Metastatic Non-small Cell Lung Cancer Dr. Divya Colin7 July 2024 6:00 PM ISTNew Delhi: In a significant development, the drug major Zydus Life Sciences has got the go-ahead from the Subject Expert Committee (SEC) functional...
Bristol Myers Squibb application for subcutaneous Nivolumab validated by EMA Ruchika Sharma23 Jun 2024 10:00 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated the extension application to introduce...
Bristol Myers Squibb gets European Commission nod for Opdivo in combo with cisplatin, gemcitabine for urothelial carcinoma Ruchika Sharma30 May 2024 12:49 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with...
Nivolumab with chemotherapy improve outcomes in resectable non-small-cell lung cancer: NEJM Jacinthlyn Sylvia29 May 2024 10:00 PM ISTA new phase 3 clinical trial revealed that standard treatment with neoadjuvant nivolumab in combination with chemotherapy significantly improved the...
EMA Committee recommends nod for Bristol Myers Squibb Opdivo in combination with Cisplatin, Gemcitabine for Urothelial Carcinoma Ruchika Sharma28 April 2024 11:30 AM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
Blood test can predict risk of relapse in advanced bladder cancer patients following surgery, suggests study Dr. Kamal Kant Kohli6 April 2024 7:00 AM ISTTesting for tumour DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research...
USFDA approves Opdivo in combo with Cisplatin and Gemcitabine for first-line treatment of adult patients with metastatic Urothelial Carcinoma: Bristol Myers Squibb Ruchika Sharma9 March 2024 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab), in combination...
Bristol Myers Squibb, Immunocore Holdings ink pact to evaluate IMC-F106C, nivolumab combo in registrational Phase 3 first-line advanced cutaneous melanoma trial Ruchika Sharma25 Feb 2024 2:00 PM ISTOxfordshire: Immunocore Holdings plc, a commercial-stage biotechnology company has announced that it has entered into a clinical trial...
Subcutaneous Nivolumab as Effective as IV injection for Renal Cell Carcinoma-With Much Faster Treatment Time Dr. Kamal Kant Kohli17 Feb 2024 2:30 AM ISTSubcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment...
CDSCO Panel grants Bristol Myer Squibb's Proposal for Additional Indication of anti-cancer drug Nivolumab Dr. Divya Colin30 Jan 2024 5:30 PM ISTNew Delhi: Noting that sufficient safety data is established, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Medical Bulletin 30/January/2024 Anshika Mishra30 Jan 2024 3:00 PM ISTHere are the top medical news of the day:Liquid biopsies to detect Neuroblastoma relapse of childhood cancer earlyCancer Research UK-funded scientists...
